Skip to main content
Erschienen in:

21.06.2022 | Review

miRNAs as therapeutic predictors and prognostic biomarkers of neoadjuvant chemotherapy in breast cancer: a systematic review and meta-analysis

verfasst von: Zhuo Zhang, Hanxu Zhang, Jiao Yu, Ling Xu, Xiaocong Pang, Qian Xiang, Qianxin Liu, Yimin Cui

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 3/2022

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Accumulating evidence has shown that microRNAs (miRNAs) are promising biomarkers of neoadjuvant chemotherapy (NAC) response in breast cancer (BC). However, their predictive roles remain controversial. Thus, this systematic review and meta-analysis aimed to describe the role of miRNA expression in NAC response and prognosis in BC to increase statistical power and improve translation.

Methods

A systematic review of electronic databases for relevant studies was conducted following PRISMA guidelines. Data were extracted, collated, and combined by odds ratio (OR) and hazard ratio (HR) with 95% confidence intervals (CIs) to estimate the strength of the associations.

Results

Of the 560 articles screened, 59 studies were included in our systematic review, and 5 studies were included in the subsequent meta-analysis. Sixty of 123 miRNAs were found to be related with NAC response and an elevated baseline miR-7 level in tissues was associated with a higher pathological complete response rate (OR 5.63; 95% CI 2.15–14.79; P = 0.0004). The prognostic value of 39 miRNAs was also studied. Of them, 26 miRNAs were found to be associated with survival. Pooled HRs indicated that patients with increased levels of serum miR-21 from baseline to the end of the second NAC cycle and from baseline to the end of NAC had a worse disease-free survival than those with decreased levels.

Conclusion

Our results highlight that a large number of miRNAs have possible associations with NAC response and prognosis in BC patients. Further well-designed studies are needed to elucidate the molecular mechanisms underlying these associations.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
4.
Zurück zum Zitat Berruti A, Amoroso V, Gallo F, Bertaglia V, Simoncini E, Pedersini R, Ferrari L, Bottini A, Bruzzi P, Sormani MP (2014) Pathologic complete response as a potential surrogate for the clinical outcome in patients with breast cancer after neoadjuvant therapy: a meta-regression of 29 randomized prospective studies. J Clin Oncol 32:3883–3891. https://doi.org/10.1200/JCO.2014.55.2836CrossRefPubMed Berruti A, Amoroso V, Gallo F, Bertaglia V, Simoncini E, Pedersini R, Ferrari L, Bottini A, Bruzzi P, Sormani MP (2014) Pathologic complete response as a potential surrogate for the clinical outcome in patients with breast cancer after neoadjuvant therapy: a meta-regression of 29 randomized prospective studies. J Clin Oncol 32:3883–3891. https://​doi.​org/​10.​1200/​JCO.​2014.​55.​2836CrossRefPubMed
5.
Zurück zum Zitat Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, Bonnefoi H, Cameron D, Gianni L, Valagussa P, Swain SM, Prowell T, Loibl S, Wickerham DL, Bogaerts J, Baselga J, Perou C, Blumenthal G, Blohmer J, Mamounas EP, Bergh J, Semiglazov V, Justice R, Eidtmann H, Paik S, Piccart M, Sridhara R, Fasching PA, Slaets L, Tang S, Gerber B, Geyer CE Jr, Pazdur R, Ditsch N, Rastogi P, Eiermann W, von Minckwitz G (2014) Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet 384:164–172. https://doi.org/10.1016/S0140-6736(13)62422-8CrossRefPubMed Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, Bonnefoi H, Cameron D, Gianni L, Valagussa P, Swain SM, Prowell T, Loibl S, Wickerham DL, Bogaerts J, Baselga J, Perou C, Blumenthal G, Blohmer J, Mamounas EP, Bergh J, Semiglazov V, Justice R, Eidtmann H, Paik S, Piccart M, Sridhara R, Fasching PA, Slaets L, Tang S, Gerber B, Geyer CE Jr, Pazdur R, Ditsch N, Rastogi P, Eiermann W, von Minckwitz G (2014) Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet 384:164–172. https://​doi.​org/​10.​1016/​S0140-6736(13)62422-8CrossRefPubMed
6.
10.
Zurück zum Zitat Jayaraj R, Nayagam SG, Kar A, Sathyakumar S, Mohammed H, Smiti M, Sabarimurugan S, Kumarasamy C, Priyadharshini T, Gothandam KM, Ramesh N, Gupta A, Baxi S, Swamiappan S, Krishnan S (2019) Clinical theragnostic relationship between drug-resistance specific miRNA expressions, chemotherapeutic resistance, and sensitivity in breast cancer: a systematic review and meta-analysis. Cells. https://doi.org/10.3390/cells8101250CrossRefPubMedPubMedCentral Jayaraj R, Nayagam SG, Kar A, Sathyakumar S, Mohammed H, Smiti M, Sabarimurugan S, Kumarasamy C, Priyadharshini T, Gothandam KM, Ramesh N, Gupta A, Baxi S, Swamiappan S, Krishnan S (2019) Clinical theragnostic relationship between drug-resistance specific miRNA expressions, chemotherapeutic resistance, and sensitivity in breast cancer: a systematic review and meta-analysis. Cells. https://​doi.​org/​10.​3390/​cells8101250CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Muller V, Gade S, Steinbach B, Loibl S, von Minckwitz G, Untch M, Schwedler K, Lubbe K, Schem C, Fasching PA, Mau C, Pantel K, Schwarzenbach H (2014) Changes in serum levels of miR-21, miR-210, and miR-373 in HER2-positive breast cancer patients undergoing neoadjuvant therapy: a translational research project within the Geparquinto trial. Breast Cancer Res Treat 147:61–68. https://doi.org/10.1007/s10549-014-3079-3CrossRefPubMed Muller V, Gade S, Steinbach B, Loibl S, von Minckwitz G, Untch M, Schwedler K, Lubbe K, Schem C, Fasching PA, Mau C, Pantel K, Schwarzenbach H (2014) Changes in serum levels of miR-21, miR-210, and miR-373 in HER2-positive breast cancer patients undergoing neoadjuvant therapy: a translational research project within the Geparquinto trial. Breast Cancer Res Treat 147:61–68. https://​doi.​org/​10.​1007/​s10549-014-3079-3CrossRefPubMed
16.
Zurück zum Zitat Garcia-Garcia F, Salinas-Vera YM, Garcia-Vazquez R, Marchat LA, Rodriguez-Cuevas S, Lopez-Gonzalez JS, Carlos-Reyes A, Ramos-Payan R, Aguilar-Medina M, Perez-Plasencia C, Ruiz-Garcia E, Lopez-Camarillo C (2019) miR1455p is associated with pathological complete response to neoadjuvant chemotherapy and impairs cell proliferation by targeting TGFbetaR2 in breast cancer. Oncol Rep 41:3527–3534. https://doi.org/10.3892/or.2019.7102CrossRefPubMed Garcia-Garcia F, Salinas-Vera YM, Garcia-Vazquez R, Marchat LA, Rodriguez-Cuevas S, Lopez-Gonzalez JS, Carlos-Reyes A, Ramos-Payan R, Aguilar-Medina M, Perez-Plasencia C, Ruiz-Garcia E, Lopez-Camarillo C (2019) miR1455p is associated with pathological complete response to neoadjuvant chemotherapy and impairs cell proliferation by targeting TGFbetaR2 in breast cancer. Oncol Rep 41:3527–3534. https://​doi.​org/​10.​3892/​or.​2019.​7102CrossRefPubMed
24.
Zurück zum Zitat Jung EJ, Santarpia L, Kim J, Esteva FJ, Moretti E, Buzdar AU, Di Leo A, Le XF, Bast RC Jr, Park ST, Pusztai L, Calin GA (2012) Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients. Cancer 118:2603–2614. https://doi.org/10.1002/cncr.26565CrossRefPubMed Jung EJ, Santarpia L, Kim J, Esteva FJ, Moretti E, Buzdar AU, Di Leo A, Le XF, Bast RC Jr, Park ST, Pusztai L, Calin GA (2012) Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients. Cancer 118:2603–2614. https://​doi.​org/​10.​1002/​cncr.​26565CrossRefPubMed
27.
Zurück zum Zitat Wu X, Somlo G, Yu Y, Palomares MR, Li AX, Zhou W, Chow A, Yen Y, Rossi JJ, Gao H, Wang J, Yuan YC, Frankel P, Li S, Ashing-Giwa KT, Sun G, Wang Y, Smith R, Robinson K, Ren X, Wang SE (2012) De novo sequencing of circulating miRNAs identifies novel markers predicting clinical outcome of locally advanced breast cancer. J Transl Med 10:42. https://doi.org/10.1186/1479-5876-10-42CrossRefPubMedPubMedCentral Wu X, Somlo G, Yu Y, Palomares MR, Li AX, Zhou W, Chow A, Yen Y, Rossi JJ, Gao H, Wang J, Yuan YC, Frankel P, Li S, Ashing-Giwa KT, Sun G, Wang Y, Smith R, Robinson K, Ren X, Wang SE (2012) De novo sequencing of circulating miRNAs identifies novel markers predicting clinical outcome of locally advanced breast cancer. J Transl Med 10:42. https://​doi.​org/​10.​1186/​1479-5876-10-42CrossRefPubMedPubMedCentral
28.
Zurück zum Zitat Zhu Y, Wu J, Li S, Ma R, Cao H, Ji M, Jing C, Tang J (2013) The function role of miR-181a in chemosensitivity to adriamycin by targeting Bcl-2 in low-invasive breast cancer cells. Cell Physiol Biochem Int J Exp Cell Physiol Biochem Pharmacol 32:1225–1237. https://doi.org/10.1159/000354521CrossRef Zhu Y, Wu J, Li S, Ma R, Cao H, Ji M, Jing C, Tang J (2013) The function role of miR-181a in chemosensitivity to adriamycin by targeting Bcl-2 in low-invasive breast cancer cells. Cell Physiol Biochem Int J Exp Cell Physiol Biochem Pharmacol 32:1225–1237. https://​doi.​org/​10.​1159/​000354521CrossRef
33.
Zurück zum Zitat Palmieri C, Cleator S, Kilburn LS, Kim SB, Ahn SH, Beresford M, Gong G, Mansi J, Mallon E, Reed S, Mousa K, Fallowfield L, Cheang M, Morden J, Page K, Guttery DS, Rghebi B, Primrose L, Shaw JA, Thompson AM, Bliss JM, Coombes RC (2014) NEOCENT: a randomised feasibility and translational study comparing neoadjuvant endocrine therapy with chemotherapy in ER-rich postmenopausal primary breast cancer. Breast Cancer Res Treat 148:581–590. https://doi.org/10.1007/s10549-014-3183-4CrossRefPubMed Palmieri C, Cleator S, Kilburn LS, Kim SB, Ahn SH, Beresford M, Gong G, Mansi J, Mallon E, Reed S, Mousa K, Fallowfield L, Cheang M, Morden J, Page K, Guttery DS, Rghebi B, Primrose L, Shaw JA, Thompson AM, Bliss JM, Coombes RC (2014) NEOCENT: a randomised feasibility and translational study comparing neoadjuvant endocrine therapy with chemotherapy in ER-rich postmenopausal primary breast cancer. Breast Cancer Res Treat 148:581–590. https://​doi.​org/​10.​1007/​s10549-014-3183-4CrossRefPubMed
35.
Zurück zum Zitat De Mattos-Arruda L, Bottai G, Nuciforo PG, Di Tommaso L, Giovannetti E, Peg V, Losurdo A, Perez-Garcia J, Masci G, Corsi F, Cortes J, Seoane J, Calin GA, Santarpia L (2015) MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients. Oncotarget 6:37269–37280. https://doi.org/10.18632/oncotarget.5495CrossRefPubMedPubMedCentral De Mattos-Arruda L, Bottai G, Nuciforo PG, Di Tommaso L, Giovannetti E, Peg V, Losurdo A, Perez-Garcia J, Masci G, Corsi F, Cortes J, Seoane J, Calin GA, Santarpia L (2015) MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients. Oncotarget 6:37269–37280. https://​doi.​org/​10.​18632/​oncotarget.​5495CrossRefPubMedPubMedCentral
43.
Zurück zum Zitat Li S, Bi T, Wang R, Gao X, Zhou J (2016) Circulating miR-663 as a novel biomarker for chemo-resistance in breast cancer of neoadjuvant chemotherapy. Int J Clin Exp Med 9:4002–4008 Li S, Bi T, Wang R, Gao X, Zhou J (2016) Circulating miR-663 as a novel biomarker for chemo-resistance in breast cancer of neoadjuvant chemotherapy. Int J Clin Exp Med 9:4002–4008
44.
Zurück zum Zitat Sha LY, Zhang Y, Wang W, Sui X, Liu SK, Wang T, Zhang H (2016) miR-18a upregulation decreases Dicer expression and confers paclitaxel resistance in triple negative breast cancer. Eur Rev Med Pharmacol Sci 20:2201–2208PubMed Sha LY, Zhang Y, Wang W, Sui X, Liu SK, Wang T, Zhang H (2016) miR-18a upregulation decreases Dicer expression and confers paclitaxel resistance in triple negative breast cancer. Eur Rev Med Pharmacol Sci 20:2201–2208PubMed
46.
Zurück zum Zitat Garcia-Vazquez R, Ruiz-Garcia E, Meneses Garcia A, Astudillo-de la Vega H, Lara-Medina F, Alvarado-Miranda A, Maldonado-Martinez H, Gonzalez-Barrios JA, Campos-Parra AD, Rodriguez Cuevas S, Marchat LA, Lopez-Camarillo C (2017) A microRNA signature associated with pathological complete response to novel neoadjuvant therapy regimen in triple-negative breast cancer. Tumour Biol J Int Soc Oncodev Biol Med 39:1010428317702899. https://doi.org/10.1177/1010428317702899CrossRef Garcia-Vazquez R, Ruiz-Garcia E, Meneses Garcia A, Astudillo-de la Vega H, Lara-Medina F, Alvarado-Miranda A, Maldonado-Martinez H, Gonzalez-Barrios JA, Campos-Parra AD, Rodriguez Cuevas S, Marchat LA, Lopez-Camarillo C (2017) A microRNA signature associated with pathological complete response to novel neoadjuvant therapy regimen in triple-negative breast cancer. Tumour Biol J Int Soc Oncodev Biol Med 39:1010428317702899. https://​doi.​org/​10.​1177/​1010428317702899​CrossRef
48.
Zurück zum Zitat Ohzawa H, Miki A, Teratani T, Shiba S, Sakuma Y, Nishimura W, Noda Y, Fukushima N, Fujii H, Hozumi Y, Mukai H, Yasuda Y (2017) Usefulness of miRNA profiles for predicting pathological responses to neoadjuvant chemotherapy in patients with human epidermal growth factor receptor 2-positive breast cancer. Oncol Lett 13:1731–1740. https://doi.org/10.3892/ol.2017.5628CrossRefPubMedPubMedCentral Ohzawa H, Miki A, Teratani T, Shiba S, Sakuma Y, Nishimura W, Noda Y, Fukushima N, Fujii H, Hozumi Y, Mukai H, Yasuda Y (2017) Usefulness of miRNA profiles for predicting pathological responses to neoadjuvant chemotherapy in patients with human epidermal growth factor receptor 2-positive breast cancer. Oncol Lett 13:1731–1740. https://​doi.​org/​10.​3892/​ol.​2017.​5628CrossRefPubMedPubMedCentral
52.
Zurück zum Zitat Stevic I, Muller V, Weber K, Fasching PA, Karn T, Marme F, Schem C, Stickeler E, Denkert C, van Mackelenbergh M, Salat C, Schneeweiss A, Pantel K, Loibl S, Untch M, Schwarzenbach H (2018) Specific microRNA signatures in exosomes of triple-negative and HER2-positive breast cancer patients undergoing neoadjuvant therapy within the GeparSixto trial. BMC Med 16:179. https://doi.org/10.1186/s12916-018-1163-yCrossRefPubMedPubMedCentral Stevic I, Muller V, Weber K, Fasching PA, Karn T, Marme F, Schem C, Stickeler E, Denkert C, van Mackelenbergh M, Salat C, Schneeweiss A, Pantel K, Loibl S, Untch M, Schwarzenbach H (2018) Specific microRNA signatures in exosomes of triple-negative and HER2-positive breast cancer patients undergoing neoadjuvant therapy within the GeparSixto trial. BMC Med 16:179. https://​doi.​org/​10.​1186/​s12916-018-1163-yCrossRefPubMedPubMedCentral
55.
Zurück zum Zitat Di Cosimo S, Appierto V, Pizzamiglio S, Tiberio P, Iorio MV, Hilbers F, de Azambuja E, de la Pena L, Izquierdo M, Huober J, Baselga J, Piccart M, de Braud FG, Apolone G, Verderio P, Daidone MG (2019) Plasma miRNA levels for predicting therapeutic response to neoadjuvant treatment in HER2-positive breast cancer: results from the NeoALTTO Trial. Clin Cancer Res Off J Am Assoc Cancer Res 25:3887–3895. https://doi.org/10.1158/1078-0432.CCR-18-2507CrossRef Di Cosimo S, Appierto V, Pizzamiglio S, Tiberio P, Iorio MV, Hilbers F, de Azambuja E, de la Pena L, Izquierdo M, Huober J, Baselga J, Piccart M, de Braud FG, Apolone G, Verderio P, Daidone MG (2019) Plasma miRNA levels for predicting therapeutic response to neoadjuvant treatment in HER2-positive breast cancer: results from the NeoALTTO Trial. Clin Cancer Res Off J Am Assoc Cancer Res 25:3887–3895. https://​doi.​org/​10.​1158/​1078-0432.​CCR-18-2507CrossRef
56.
Zurück zum Zitat Garcia-Vazquez R, Marchat LA, Ruiz-Garcia E, Astudillo-de la Vega H, Meneses-Garcia A, Arce-Salinas C, Bargallo-Rocha E, Carlos-Reyes A, Lopez-Gonzalez JS, Perez-Plasencia C, Ramos-Payan R, Aguilar-Medina M, Lopez-Camarillo C (2019) MicroRNA-143 is associated with pathological complete response and regulates multiple signaling proteins in breast cancer. Technol Cancer Res Treat 18:1533033819827309. https://doi.org/10.1177/1533033819827309CrossRefPubMedPubMedCentral Garcia-Vazquez R, Marchat LA, Ruiz-Garcia E, Astudillo-de la Vega H, Meneses-Garcia A, Arce-Salinas C, Bargallo-Rocha E, Carlos-Reyes A, Lopez-Gonzalez JS, Perez-Plasencia C, Ramos-Payan R, Aguilar-Medina M, Lopez-Camarillo C (2019) MicroRNA-143 is associated with pathological complete response and regulates multiple signaling proteins in breast cancer. Technol Cancer Res Treat 18:1533033819827309. https://​doi.​org/​10.​1177/​1533033819827309​CrossRefPubMedPubMedCentral
58.
Zurück zum Zitat Huang J, Zhao M, Hu H, Wang J, Ang L, Zheng L (2019) MicroRNA-130a reduces drug resistance in breast cancer. Int J Clin Exp Pathol 12:2699–2705PubMedPubMedCentral Huang J, Zhao M, Hu H, Wang J, Ang L, Zheng L (2019) MicroRNA-130a reduces drug resistance in breast cancer. Int J Clin Exp Pathol 12:2699–2705PubMedPubMedCentral
61.
Zurück zum Zitat Luengo-Gil G, Garcia-Martinez E, Chaves-Benito A, Conesa-Zamora P, Navarro-Manzano E, Gonzalez-Billalabeitia E, Garcia-Garre E, Martinez-Carrasco A, Vicente V, Ayala de la Pena F (2019) Clinical and biological impact of miR-18a expression in breast cancer after neoadjuvant chemotherapy. Cell Oncol (Dordr) 42:627–644. https://doi.org/10.1007/s13402-019-00450-2CrossRef Luengo-Gil G, Garcia-Martinez E, Chaves-Benito A, Conesa-Zamora P, Navarro-Manzano E, Gonzalez-Billalabeitia E, Garcia-Garre E, Martinez-Carrasco A, Vicente V, Ayala de la Pena F (2019) Clinical and biological impact of miR-18a expression in breast cancer after neoadjuvant chemotherapy. Cell Oncol (Dordr) 42:627–644. https://​doi.​org/​10.​1007/​s13402-019-00450-2CrossRef
62.
Zurück zum Zitat Rodriguez-Martinez A, de Miguel-Perez D, Ortega FG, Garcia-Puche JL, Robles-Fernandez I, Exposito J, Martorell-Marugan J, Carmona-Saez P, Garrido-Navas MDC, Rolfo C, Ilyine H, Lorente JA, Legueren M, Serrano MJ (2019) Exosomal miRNA profile as complementary tool in the diagnostic and prediction of treatment response in localized breast cancer under neoadjuvant chemotherapy. Breast Cancer Res 21:21. https://doi.org/10.1186/s13058-019-1109-0CrossRefPubMedPubMedCentral Rodriguez-Martinez A, de Miguel-Perez D, Ortega FG, Garcia-Puche JL, Robles-Fernandez I, Exposito J, Martorell-Marugan J, Carmona-Saez P, Garrido-Navas MDC, Rolfo C, Ilyine H, Lorente JA, Legueren M, Serrano MJ (2019) Exosomal miRNA profile as complementary tool in the diagnostic and prediction of treatment response in localized breast cancer under neoadjuvant chemotherapy. Breast Cancer Res 21:21. https://​doi.​org/​10.​1186/​s13058-019-1109-0CrossRefPubMedPubMedCentral
64.
Zurück zum Zitat Di Cosimo S, Appierto V, Pizzamiglio S, Silvestri M, Baselga J, Piccart M, Huober J, Izquierdo M, de la Pena L, Hilbers FS, de Azambuja E, Untch M, Pusztai L, Pritchard K, Nuciforo P, Vincent-Salomon A, Symmans F, Apolone G, de Braud FG, Iorio MV, Verderio P, Daidone MG (2020) Early modulation of circulating microRNAs levels in HER2-positive breast cancer patients treated with trastuzumab-based neoadjuvant therapy. Int J Mol Sci. https://doi.org/10.3390/ijms21041386CrossRefPubMedPubMedCentral Di Cosimo S, Appierto V, Pizzamiglio S, Silvestri M, Baselga J, Piccart M, Huober J, Izquierdo M, de la Pena L, Hilbers FS, de Azambuja E, Untch M, Pusztai L, Pritchard K, Nuciforo P, Vincent-Salomon A, Symmans F, Apolone G, de Braud FG, Iorio MV, Verderio P, Daidone MG (2020) Early modulation of circulating microRNAs levels in HER2-positive breast cancer patients treated with trastuzumab-based neoadjuvant therapy. Int J Mol Sci. https://​doi.​org/​10.​3390/​ijms21041386CrossRefPubMedPubMedCentral
65.
Zurück zum Zitat Ibrahim AM, Said MM, Hilal AM, Medhat AM, Abd Elsalam IM (2020) Candidate circulating microRNAs as potential diagnostic and predictive biomarkers for the monitoring of locally advanced breast cancer patients. Tumour Biol J Int Soc Oncodev Biol Med 42:1010428320963811. https://doi.org/10.1177/1010428320963811CrossRef Ibrahim AM, Said MM, Hilal AM, Medhat AM, Abd Elsalam IM (2020) Candidate circulating microRNAs as potential diagnostic and predictive biomarkers for the monitoring of locally advanced breast cancer patients. Tumour Biol J Int Soc Oncodev Biol Med 42:1010428320963811. https://​doi.​org/​10.​1177/​1010428320963811​CrossRef
66.
Zurück zum Zitat McGuire A, Casey MC, Waldron RM, Heneghan H, Kalinina O, Holian E, McDermott A, Lowery AJ, Newell J, Dwyer RM, Miller N, Keane M, Brown JAL, Kerin MJ (2020) Prospective assessment of systemic microRNAs as markers of response to neoadjuvant chemotherapy in breast cancer. Cancers (Basel). https://doi.org/10.3390/cancers12071820CrossRef McGuire A, Casey MC, Waldron RM, Heneghan H, Kalinina O, Holian E, McDermott A, Lowery AJ, Newell J, Dwyer RM, Miller N, Keane M, Brown JAL, Kerin MJ (2020) Prospective assessment of systemic microRNAs as markers of response to neoadjuvant chemotherapy in breast cancer. Cancers (Basel). https://​doi.​org/​10.​3390/​cancers12071820CrossRef
68.
75.
Zurück zum Zitat Zhang HL, Yang LF, Zhu Y, Yao XD, Zhang SL, Dai B, Zhu YP, Shen YJ, Shi GH, Ye DW (2011) Serum miRNA-21: elevated levels in patients with metastatic hormone-refractory prostate cancer and potential predictive factor for the efficacy of docetaxel-based chemotherapy. Prostate 71:326–331. https://doi.org/10.1002/pros.21246CrossRefPubMed Zhang HL, Yang LF, Zhu Y, Yao XD, Zhang SL, Dai B, Zhu YP, Shen YJ, Shi GH, Ye DW (2011) Serum miRNA-21: elevated levels in patients with metastatic hormone-refractory prostate cancer and potential predictive factor for the efficacy of docetaxel-based chemotherapy. Prostate 71:326–331. https://​doi.​org/​10.​1002/​pros.​21246CrossRefPubMed
80.
Metadaten
Titel
miRNAs as therapeutic predictors and prognostic biomarkers of neoadjuvant chemotherapy in breast cancer: a systematic review and meta-analysis
verfasst von
Zhuo Zhang
Hanxu Zhang
Jiao Yu
Ling Xu
Xiaocong Pang
Qian Xiang
Qianxin Liu
Yimin Cui
Publikationsdatum
21.06.2022
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 3/2022
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-022-06642-z

Neu im Fachgebiet Onkologie

Neue chemotherapiefreie Kombinationstherapie punktet bei CLL

Zwischenergebnisse der Phase-III-Studie AMPLIFY sprechen dafür, dass die zeitlich begrenzte Behandlung mit Acalabrutinib und Venetoclax fitte Personen mit chronischer lymphatischer Leukämie länger leben lässt als eine Chemoimmuntherapie.

NRG1-Fusionen als neues, klinisch relevantes Target

Ergebnisse einer Phase-II-Studie deuten darauf hin, dass ein gegen HER3 und HER2 gerichteter Antikörper bei verschiedenen NRG1-Fusions-positiven Tumoren wirksam sein könnte. In den USA ist die Substanz bereits beschleunigt zugelassen worden.

Die aktuelle S3-Leitlinie zu CLL strotzt vor Neuerungen

Vor kurzem wurde eine neue, grundlegend überarbeite Version der S3-Leitlinie Chronische Lymphatische Leukämie (CLL) veröffentlicht.  Zu den wichtigsten Änderungen gehört, dass die Chemoimmuntherapie auf dem Rückzug ist.

Gluteuslappen nach Rektumkarzinom-Op. schützt vor Abszessen

Die Wunddeckung mit einem autologen Rotationslappen nach Entfernung eines Rektumkarzinoms konnte in einer randomisierten Studie gegenüber dem primären Wundverschluss vor allem in einer Hinsicht punkten: Sie führte deutlich seltener zu präsakralen Abszessen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.